Document is current

Article History

Accepted: 9 August 2022

First Online: 10 September 2022

Declarations

:

: Assistance with the preparation of this manuscript was funded by Novartis, Japan.

: Makoto Nishio has received Grants and personal fees from AstraZeneca, Bristol Myers Squibb, Chugai Pharmaceutical, Daiichi Sankyo, Eli Lilly, MSD, Novartis, Ono Pharmaceutical, Pfizer, Takeda Pharmaceutical Company Limited, and Taiho Pharmaceutical; and personal fees from AbbVie, Boehringer-Ingelheim, Merck Biopharma, and TEIJIN PHARMA LIMITED, outside the submitted work. Terufumi Kato has received Grants and personal fees from Abbvie, Amgen, AstraZeneca, Bristol Myers Squibb, Chugai, Eli Lilly, Merck Biopharma, MSD, Novartis, Ono, Pfizer, and Taiho; Grants from Regeneron; and personal fees from Boehringer Ingelheim, Daiichi-Sankyo, Nippon Kayaku, and Takeda. Ryo Toyozawa has received honoraria for lectures from Bristol-Myers Squibb, Chugai Pharmaceutical, Eli Lilly Japan, Kyowa Hakko Kirin, MSD, Nippon Boehringer Ingelheim, Nippon Kayaku, Novartis Pharma, and Taiho Pharmaceutical; and his institution has received Grants from Abbvie, Amgen, Daiichi Sankyo, Eli Lilly Japan, Novartis Pharma, Pfizer Japan, and Takeda Pharmaceutical. Toyoaki Hida has received Grants and personal fees from Novartis, Merck, AstraZeneca and Pfizer.

: Not applicable.

: Not applicable.

: Not applicable.

: Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

: Not applicable.

: All authors contributed to the focus and scope, as well as concept of this review. All authors reviewed the text for intellectual content, read and approved drafts, and take responsibility for the content of the review.